IL148416A0 - Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders - Google Patents

Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders

Info

Publication number
IL148416A0
IL148416A0 IL14841600A IL14841600A IL148416A0 IL 148416 A0 IL148416 A0 IL 148416A0 IL 14841600 A IL14841600 A IL 14841600A IL 14841600 A IL14841600 A IL 14841600A IL 148416 A0 IL148416 A0 IL 148416A0
Authority
IL
Israel
Prior art keywords
mesoprogestins
prevention
treatment
receptor modulators
progesterone receptor
Prior art date
Application number
IL14841600A
Other languages
English (en)
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of IL148416A0 publication Critical patent/IL148416A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
IL14841600A 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders IL148416A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31
PCT/US2000/023770 WO2001015679A2 (en) 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Publications (1)

Publication Number Publication Date
IL148416A0 true IL148416A0 (en) 2002-09-12

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14841600A IL148416A0 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders

Country Status (34)

Country Link
EP (1) EP1229906B1 (lt)
JP (1) JP2003535029A (lt)
KR (3) KR20080066095A (lt)
AR (1) AR025457A1 (lt)
AT (1) ATE375160T1 (lt)
AU (1) AU781840B2 (lt)
BG (1) BG65817B1 (lt)
BR (1) BR0014161A (lt)
CA (1) CA2382580C (lt)
CO (1) CO5200772A1 (lt)
CZ (1) CZ2002704A3 (lt)
DE (1) DE60036723T2 (lt)
DK (1) DK1229906T3 (lt)
EA (1) EA007854B1 (lt)
EE (1) EE05172B1 (lt)
ES (1) ES2295050T3 (lt)
HR (1) HRP20020267A2 (lt)
HU (1) HUP0202429A3 (lt)
IL (1) IL148416A0 (lt)
LT (1) LT5034B (lt)
LV (1) LV12941B (lt)
ME (1) MEP13808A (lt)
MX (1) MXPA02002191A (lt)
NO (1) NO20020999L (lt)
NZ (1) NZ517471A (lt)
PE (1) PE20010578A1 (lt)
PL (1) PL198790B1 (lt)
PT (1) PT1229906E (lt)
RO (1) RO122179B1 (lt)
RS (1) RS50283B (lt)
SI (1) SI20852B (lt)
SK (1) SK287192B6 (lt)
UA (1) UA78184C2 (lt)
WO (1) WO2001015679A2 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014935A1 (de) * 2002-08-02 2004-02-19 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
AU2010260885B2 (en) * 2009-06-17 2015-03-12 Keio University Prophylactic and/or therapeutic agent for dysmenorrhea
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
WO1996019458A2 (en) * 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5696130A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
SK282570B6 (sk) 1995-02-02 2002-10-08 Schering Aktiengesellschaft Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
DE69702450T2 (de) * 1996-05-01 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer 21-substituierte progesteron derivate als antigestagene
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
BR9916999A (pt) * 1999-01-14 2001-10-30 Bayer Ag Heterociclos de 2-arilimino substituìdos ecomposições contendo-os, para uso como agentesde ligação do receptor de progesterona
WO2000066590A2 (en) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
HUP0202429A2 (en) 2002-10-28
JP2003535029A (ja) 2003-11-25
YU14002A (sh) 2006-01-16
BG65817B1 (bg) 2010-01-29
AR025457A1 (es) 2002-11-27
SK287192B6 (sk) 2010-02-08
SI20852A (sl) 2002-10-31
ES2295050T3 (es) 2008-04-16
EE200200104A (et) 2003-04-15
LT2002031A (lt) 2003-02-25
KR100864547B1 (ko) 2008-10-20
AU781840B2 (en) 2005-06-16
MXPA02002191A (es) 2002-09-30
NZ517471A (en) 2004-02-27
EA200200282A1 (ru) 2002-10-31
PE20010578A1 (es) 2001-06-04
UA78184C2 (en) 2007-03-15
LV12941B (en) 2003-06-20
MEP13808A (en) 2010-06-10
NO20020999D0 (no) 2002-02-28
ATE375160T1 (de) 2007-10-15
KR20080066095A (ko) 2008-07-15
SI20852B (sl) 2009-06-30
SK2992002A3 (en) 2002-07-02
KR100755109B1 (ko) 2007-09-04
PL353930A1 (en) 2003-12-15
WO2001015679A3 (en) 2001-11-22
LT5034B (lt) 2003-07-25
CA2382580A1 (en) 2001-03-08
HUP0202429A3 (en) 2004-04-28
DE60036723T2 (de) 2008-07-17
EA007854B1 (ru) 2007-02-27
CO5200772A1 (es) 2002-09-27
DE60036723D1 (de) 2007-11-22
DK1229906T3 (da) 2008-02-11
NO20020999L (no) 2002-03-14
CA2382580C (en) 2009-05-19
BR0014161A (pt) 2002-05-21
WO2001015679A2 (en) 2001-03-08
EP1229906B1 (en) 2007-10-10
BG106442A (bg) 2002-09-30
CZ2002704A3 (cs) 2003-02-12
HRP20020267A2 (en) 2004-04-30
RS50283B (sr) 2009-09-08
KR20020027616A (ko) 2002-04-13
PL198790B1 (pl) 2008-07-31
EE05172B1 (et) 2009-06-15
EP1229906A2 (en) 2002-08-14
RO122179B1 (ro) 2009-02-27
AU6946600A (en) 2001-03-26
KR20070058023A (ko) 2007-06-07
PT1229906E (pt) 2008-01-18

Similar Documents

Publication Publication Date Title
ZA200201053B (en) Bicyclic androgen and progesterone receptor modulator compounds and methods.
EG25606A (en) Glucocorticoid receptor modulators
HUP0103345A3 (en) Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions
AU3086900A (en) Device for the complex treatment of disorders of the prostate
CA2261263A1 (en) Use of sex steroid function modulators to treat wounds and fibrotic disorders
HUP0001748A3 (en) Transdermal device for the delivery of testosterone
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
HU9803018D0 (en) Methods and compositions for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
PL348113A1 (en) Drug delivery device, especially for the delivery of progestins and estrogens
HUP0103222A3 (en) Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
AU4134101A (en) Hormone receptor functional entities and methods of their use
AU5025300A (en) Compositions for controlled release of the hormone gnrh and its analogs
MXPA01011294A (es) Compuestos moduladores de receptor de progesterona tetraciclicos y metodos.
HRP20020267A2 (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
EP1117429A4 (en) CHEMOKINE RECEPTOR PEPTIDE VACCINES FOR TREATING AND PREVENTING DIABETES
AU6766900A (en) Cd39/ecto-adpase for treatment of thrombotic and ischemic disorders
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
AU7601400A (en) Treatment and prevention of hepatic disorders
AU2002235348A1 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
HUP0202515A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
AU2736095A (en) Device for the external fixation of extremities and extremity zones and pad for lining the device
GB2353471B (en) Composition for treating obesity and related disorders and using therof
IL146280A0 (en) Cyclocarbamate derivatives as progesterone receptor modulators
AU2435899A (en) Device for preventing undesired release of liquid